As per MRFR analysis, the US Angioplasty Balloons Market Size was estimated at 398.44 (USD Million) in 2023. The US Angioplasty Balloons Market Industry is expected to grow from 450(USD Million) in 2024 to 750 (USD Million) by 2035. The US Angioplasty Balloons Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035).
The US Angioplasty Balloons Market has been experiencing notable trends driven by an increasing prevalence of cardiovascular diseases. An aging population coupled with lifestyle factors such as obesity and diabetes has significantly raised the demand for angioplasty procedures. Furthermore, there is a growing emphasis on minimally invasive surgeries, leading to an increased adoption of angioplasty balloons due to their effectiveness in treating narrowed arteries with reduced recovery time for patients.
Advancements in technology are also shaping the market, with innovations such as drug-eluting balloons and bioresorbable materials gaining traction. These developments enhance treatment outcomes and reduce the risk of restenosis. The rise of telemedicine and remote patient monitoring systems has bolstered patient awareness and compliance, encouraging more individuals to seek treatments for cardiovascular issues and subsequently driving the market.
Opportunities for growth in the US Angioplasty Balloons Market can be captured through enhanced collaborations between manufacturers and healthcare providers for clinical trials, improving product effectiveness and patient outcomes. Additionally, increasing investments in research and development present a pathway for companies to innovate and offer advanced product solutions.
Recent times have shown increasing regulatory support for advanced angioplasty devices, promoting innovation while ensuring patient safety. This regulatory clarity encourages new entrants in the market, fostering a competitive environment that can lead to better products and services. Overall, the combination of a rising patient base, technological advancements, and supportive regulatory frameworks presents a dynamic landscape for the US Angioplasty Balloons Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Angioplasty Balloons Market Industry is significantly driven by the increasing prevalence of cardiovascular diseases (CVDs), which remain among the leading causes of death in the United States. According to the Centers for Disease Control and Prevention (CDC), nearly 697,000 people died from heart disease in 2020, accounting for 1 in every 5 deaths.
This alarming statistic highlights a growing patient population that necessitates effective treatment options, including angioplasty balloons. Moreover, advancements in diagnostic technologies and an increase in screening practices have led to earlier detection of heart diseases, thereby amplifying the demand for angioplasty procedures. The American Heart Association (AHA) reports that the number of coronary angioplasty procedures performed annually has been steadily increasing, thereby propelling the US Angioplasty Balloons Market forward. The convergence of these factors suggests a robust future growth trajectory for the industry.
Technological advancements in the design and manufacturing of angioplasty balloons are a crucial driver for the US Angioplasty Balloons Market Industry. Newer technologies such as drug-coated balloons (DCBs) and bioabsorbable balloons have emerged, offering enhanced efficacy and reduced complications during procedures.
As reported by the Food and Drug Administration (FDA), drug-coated balloons have shown to significantly decrease the rate of restenosis in patients, a common concern that leads to repeated interventions. The introduction of these innovative products has also attracted key players in the market who are investing heavily in Research and Development (R&D) to stay ahead of the competition. For example, established organizations like Boston Scientific and Medtronic have made considerable advancements in balloon technology, contributing to the overall growth of the angioplasty market in the US.
Heightened awareness about heart health and preventive healthcare measures plays a pivotal role in driving the US Angioplasty Balloons Market Industry. Initiatives led by organizations such as the CDC and AHA aim to educate the American public on the risks associated with cardiovascular diseases and the importance of early intervention.
As a result, there has been a marked increase in the number of people seeking preventive check-ups and adopting heart-healthy lifestyles. This growing trend is supported by recent surveys that indicate over 60% of adults are now aware of their cholesterol levels and cardiovascular risk factors. As more individuals undergo routine screenings, early signs of cardiovascular issues are identified, leading to an increased incidence of angioplasty procedures and subsequently driving market growth.
Supportive government policies and favorable reimbursement frameworks are essential in augmenting the US Angioplasty Balloons Market Industry. Various healthcare reforms aim to enhance access to preventive services and treatment options for cardiovascular diseases. According to healthcare policy analysts, there has been an improvement in federal and state-level reimbursements for angioplasty procedures, making them more accessible to patients.
This is particularly evident in Medicare and Medicaid programs, which have recognized the importance of angioplasty in treating coronary artery disease. The result is a more robust healthcare environment that supports healthcare providers and patients alike, leading to increased usage of angioplasty balloons in the US market.
The US Angioplasty Balloons Market has seen significant evolution in recent years, particularly in the Type segment which includes Drug-Eluting Balloons, Plain Old Balloons, and Scoring Balloons. The Drug-Eluting Balloons segment is particularly noteworthy as it combines the mechanical action of balloon dilation with localized drug delivery. This has led to improved outcomes in patients with complex lesions, and its adoption has been growing steadily due to advancements in drug formulations and balloon technologies. It plays a crucial role in reducing the rates of restenosis, making it a vital tool in the treatment of coronary artery diseases.
On the other hand, Plain Old Balloons have maintained a strong presence in the market for their simplicity and efficacy in specific conditions. They are cost-effective and often used in various clinical settings, contributing to their popularity among healthcare providers. The Scoring Balloons segment stands out due to its unique design features, which allow for enhanced plaque modification and improved vessel wall expansion. This technology is particularly beneficial for patients with fibrous plaques whom traditional balloons may struggle to treat effectively. Overall, the segmentation within the US Angioplasty Balloons Market highlights the diverse approaches to angioplasty interventions, catering to different clinical needs and embracing innovation to enhance patient outcomes. As each sub-segment continues to develop, a keen focus on clinical efficacy and safety will likely guide future market dynamics.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Angioplasty Balloons Market is characterized by its diverse Applications, prominently featuring Coronary Angioplasty, Peripheral Angioplasty, and Renal Angioplasty. Coronary Angioplasty is crucial as it addresses blockages in coronary arteries and plays a significant role in managing cardiovascular diseases, a leading health concern in the United States.
Peripheral Angioplasty focuses on enhancing blood flow in peripheral arteries, which is vital for patients suffering from peripheral artery disease, an issue that affects millions in the US. Lastly, Renal Angioplasty is essential for individuals with renal artery stenosis, a condition that can lead to hypertension and other complications. Market growth in these segments is propelled by the increasing prevalence of cardiovascular conditions and advancements in balloon technology that improve patient outcomes. However, challenges such as high treatment costs and complications associated with procedures persist. Overall, the emphasis on minimally invasive techniques and the growing acceptance of angioplasty procedures present significant opportunities for further development within these Applications in the US Angioplasty Balloons Market.
The US Angioplasty Balloons Market, particularly focusing on the Material segment, showcases significant diversity and innovation. This segment includes various materials such as Polymer, Latex, and Metal, each playing a crucial role in the functionality of angioplasty balloons. Polymers are gaining traction in the market due to their flexibility and biocompatibility, making them favorable for both patients and healthcare providers.
Latex, while historically used, is seeing a decline in preference due to allergy concerns, so manufacturers are now leaning toward alternatives that ensure patient safety. Metal balloons are particularly valued for their strength and durability, providing reliable performance in high-pressure situations during procedures. With an increasing number of cardiovascular interventions in the US, driven by rising incidences of heart diseases, the demand for these materials is expected to grow significantly. The focus on Research and Development is leading to advancements in material technology, enabling enhancements in balloon design and effectiveness, thereby influencing the overall US Angioplasty Balloons Market statistics.
The US Angioplasty Balloons Market, particularly focusing on the End Use segment, is showcasing diverse applications across various healthcare settings, driving significant market growth. Hospitals play a critical role in this segment as they are equipped with advanced facilities and technologies, allowing for complex angioplasty procedures and offering comprehensive post-operative care.
Ambulatory Surgical Centers are increasingly popular for less invasive procedures due to their efficiency and lower costs, providing an attractive alternative for patients requiring angioplasty. Additionally, Cardiac Catheterization Laboratories are pivotal within this market, as they facilitate specialized cardiac interventions, enhancing patient outcomes and procedural safety. This growing focus on cardiac health in the US, influenced by increasing rates of cardiovascular diseases, further underscores the importance of these facilities in the angioplasty process. The market dynamics reflect a broader trend towards outpatient care and rapid advancements in minimally invasive techniques, which are transforming patient management strategies and making these end-use settings vital in improving healthcare delivery in the United States.
The US Angioplasty Balloons Market is characterized by intense competition among various players striving to innovate and expand their market presence. This market involves significant technological advancements, including the development of specialized balloon catheters designed for various vascular interventions. With the increasing prevalence of cardiovascular diseases and the aging population, the demand for angioplasty procedures has risen sharply, leading to a flourishing market environment. Players are deploying strategies such as product differentiation, extensive research and development, and strategic partnerships to gain a competitive edge. Additionally, regulatory approvals and compliance with strict industry standards are crucial factors influencing market dynamics. As a result, understanding competitive insights within this sector is vital for stakeholders looking to navigate the landscape effectively.
Medline Industries holds a prominent position in the US Angioplasty Balloons Market, showcasing unique strengths through its robust product offerings and extensive distribution network. Known for delivering high-quality medical supplies, the company emphasizes efficiency and reliability in its angioplasty balloon products. Medline Industries leverages its established relationships with healthcare providers, hospitals, and specialty clinics, ensuring widespread accessibility and availability of its products within the United States. The company's commitment to customer service and education further enhances its competitive stance, allowing healthcare professionals to leverage best practices for optimal patient outcomes. Additionally, with a diverse portfolio that includes various medical products, Medline Industries remains adaptable to market changes and demands.
The Spectranetics Corporation features prominently in the US Angioplasty Balloons Market, focusing on innovative solutions within the realm of vascular intervention. The company is recognized for its advanced drug-coated balloon technology aimed at treating coronary and peripheral artery diseases. Key products include balloon catheters that provide targeted therapy, improving patient outcomes while minimizing complications. The Spectranetics Corporation is actively engaged in collaborations and partnerships to further enhance its product offerings, which bolsters its market presence. Strengths include a strong research and development focus and a commitment to delivering safe, effective medical devices. In recent years, the company has participated in strategic mergers and acquisitions that have strengthened its position and expanded its market reach, providing an edge in a competitive landscape.
Recent developments in the US Angioplasty Balloons Market indicate a significant focus on technological advancements and product enhancements aimed at improving patient outcomes. Companies such as Medtronic, Boston Scientific, and Abbott are actively engaging in innovation cycles, introducing new balloon designs that enhance deliverability and performance during procedures.
The ongoing trend of hospital acquisitions and partnerships has also contributed to market dynamics, with Cardinal Health acquiring specific assets from other medical device companies to expand its cardiovascular portfolio, particularly in July 2023. Notably, Medline Industries and C. R. Bard have reported increased market valuation due to rising demand for minimally invasive procedures, resulting from advancements in interventional cardiology.
Furthermore, in September 2023, it was announced that Terumo agreed to acquire certain components of the Spectranetics Corporation, strengthening its position in the angioplasty balloon sector. The US market is witnessing a surge in investments from both established players and startups, with a growing emphasis on Research and Development to address the challenges in treating cardiovascular diseases. The continued focus on regulatory approvals and clinical outcomes remains a priority within the industry, shaping the future landscape of the angioplasty balloon market in the US.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 398.44(USD Million) |
| MARKET SIZE 2024 | 450.0(USD Million) |
| MARKET SIZE 2035 | 750.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.753% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Medline Industries, The Spectranetics Corporation, B. Braun, C. R. Bard, Medtronic, Boston Scientific, Cardinal Health, Cordis, Terumo, Cook Medical, Philips, Asahi Intecc, Abbott, Spectranetics, AngioDynamics |
| SEGMENTS COVERED | Type, Application, Material, End Use |
| KEY MARKET OPPORTUNITIES | Growing elderly population demand, Advancements in balloon technology, Increased prevalence of cardiovascular diseases, Expansion of minimally invasive procedures, Rising healthcare expenditure and access |
| KEY MARKET DYNAMICS | Increasing prevalence of cardiovascular diseases, Advancements in balloon technology, Growing geriatric population, Rising demand for minimally invasive procedures, Expanding healthcare expenditure in the US |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Angioplasty Balloons Market is expected to be valued at 450.0 million USD in 2024.
By 2035, the US Angioplasty Balloons Market is projected to reach a valuation of 750.0 million USD.
The expected compound annual growth rate (CAGR) for the US Angioplasty Balloons Market from 2025 to 2035 is 4.753%.
The Drug-Eluting Balloons are expected to hold the largest market share, valued at 180.0 million USD in 2024.
By 2035, the Drug-Eluting Balloons segment is expected to grow to a value of 300.0 million USD.
The Plain Old Balloons segment is projected to be valued at 150.0 million USD in 2024.
By 2035, the Scoring Balloons segment is anticipated to reach a market value of 210.0 million USD.
Major players in the US Angioplasty Balloons Market include Medline Industries, Boston Scientific, and Medtronic among others.
Opportunities in the US Angioplasty Balloons Market are driven by advancements in technology and increasing demand for minimally invasive procedures.
Challenges in the US Angioplasty Balloons Market include regulatory hurdles and competition from alternative treatment options.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
